Translation of Protein Biomarkers for Clinical Development

Clinical Proteomics: From Diagnosis to Therapy

Volumn , Issue , 2008, Pages 633-651

  McCaffery, Ian ^a   Fitzpatrick, V Dan ^a   Wang, Shen Wu ^a   Rossi, John M ^a   Bao, Haifeng ^a   Suggs, Sid V ^a   Ferbas, John ^a   Patterson, Scott D ^a  

^a AMGEN INC   (United States)

Author keywords

Clinical development; Early drug development; Protein biomarkers

Indexed keywords

EID: 43249122563     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527622153.ch34     Document Type: Chapter

References (27)

1. Food and Drug Administration. US Department of Health and Human Services (2004) Challenges and Opportunities on the Critical Path to New Medical Products. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
2. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics, 69, 89-95.
3. Ludwig, J. A. and Weinstein, J. N. (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer, 5, 845-56.
4. Workman, P., Aboagye, E. O., Chung, Y. L., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M., Price, P. M. and Zweit, J. (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. Journal of the National Cancer Institute, 98, 580-98.
5. Lee, J. W., Devanarayan, V., Barrett, Y. C., Weiner, R., Allinson, J., Fountain, S., Keller, S., Weinryb, I., Green, M., Duan, L., Rogers, J. A., Millham, R., O'Brien, P. J., Sailstad, J., Khan, M., Ray, C. and Wagner, J. A. (2006) Fitfor-purpose method development and validation for successful biomarker measurement. Pharmaceutical Research, 23, 312-28.
6. Kingsmore, S. F. (2006) Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nature Reviews Drug Discovery, 5, 310-20.
7. Altomare, D. A. and Testa, J. R. (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene, 24, 7455-64.
8. Vivanco, I. and Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer, 2, 489-501.
9. Testa, J. R. and Tsichlis, P. N. (2005) AKT signaling in normal and malignant cells. Oncogene, 24, 7391-3.
10. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D. and Downward, J. (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature, 370, 527-32.
11. Nicholson, K. M. and Anderson, N. G. (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling, 14, 381-95.
12. Larue, L. and Bellacosa, A. (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene, 24, 7443-54.
13. Grille, S. J., Bellacosa, A., Upson, J., Klein-Szanto, A. J., van Roy, F., Lee-Kwon, W., Donowitz, M., Tsichlis, P. N. and Larue, L. (2003) The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Research, 63, 2172-8.
14. Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., Asaoka, Y., Matsumura, M., Kawabe, T. and Omata, M. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Research, 65, 4562-7.
15. Li, V. S., Wong, C. W., Chan, T. L., Chan, A. S., Zhao, W., Chu, K. M., So, S., Chen, X., Yuen, S. T. and Leung, S. Y. (2005) Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer, 5, 29.
16. Liu, Z. and Roberts, T. M. (2006) Human tumor mutants in the p110alpha subunit of PI3K. Cell Cycle, 5, 675-7.
17. Vogt, P. K., Bader, A. G. and Kang, S. (2006) Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology, 344, 131-8.
18. Costa, L. F., Balcells, M., Edelman, E. R., Nadler, L. M. and Cardoso, A. A. (2006) Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood, 107, 285-92.
19. Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A. and Armand, J. P. (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. Journal of Clinical Oncology, 22, 2336-47.
20. Faivre, S., Kroemer, G. and Raymond, E. (2006) Current development of mTOR inhibitors as anticancer agents. Nature Reviews Drug Discovery, 5, 671-88.
21. Peralba, J. M., DeGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G. and Hidalgo, M. (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clinical Cancer Research, 9, 2887-92.
22. Malik, S. N., Siu, L. L., Rowinsky, E. K., deGraffenried, L., Hammond, L. A., Rizzo, J., Bacus, S., Brattain, M. G., Kreisberg, J. I. and Hidalgo, M. (2003) Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clinical Cancer Research, 9, 2478-86.
23. Covey, T., Mu, S., Middleton, S. and Saris, C. J. M. (2005) Monitoring Signal Transduction in Whole Blood by Flow Cytometry, AAI.
24. Krutzik, P. O., Irish, J. M., Nolan, G. P. and Perez, O. D. (2004) Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clinical Immunology, 110, 206-21.
25. Krutzik, P. O. and Nolan, G. P. (2003) Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A, 55, 61-70.
26. Trepanier, D. J., Gallant, H., Legatt, D. F. and Yatscoff, R. W. (1998) Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clinical Biochemistry, 31, 345-51.
27. Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., Jaeckle, K. A., Scheithauer, B. W., Dancey, J., Hidalgo, M. and Walsh, D. J. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. Journal of Clinical Oncology, 23, 5294-304.